Global Conference 2012

Global Conference 2012

Financial Innovations for Early-Stage Drug Development

Monday, April 30, 2012 / 11:00 am - 12:15 pm

Translational research - the point at which general scientific knowledge starts to be applied to addressing a specific disease or condition - is the first step on the path to developing a new drug. But traditional investors in translational research (large- and medium-cap biopharmaceutical companies and life science-focused venture capital funds) are becoming increasingly risk averse in the face of escalating challenges in the drug development process. FasterCures recently hosted a Financial Innovations Lab to examine business models and financial instruments that can improve the risk/return ratio for early-stage investors. In this session you'll hear from experts who have designed and implemented new models like leveraged funds, research-based obligations and collaborative funding. If we can find a way to close the funding gap for translational research, we can get one step closer to urgently needed treatments.


Melissa Stevens

Deputy Executive Director, FasterCures / The Center for Accelerating Medical Solutions


Aya Jakobovits

President and CEO, Kite Pharma; Venture Partner, Orbimed Partners

Andrew Lo

Harris & Harris Group Professor, MIT Sloan School of Management

Bernard Munos

Founder, InnoThink Center for Research in Biomedical Innovation

Kathryn Smith

Managing Director, Fast Forward LLC

Chris Varma

President and CEO, Blueprint Medicines

Return to Program Detail